arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ORAMED PHARMACEUTICALS INC.

ORMP
$3.89 ▼ -0.24 (-5.81%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
80 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
42
Health
Weak
Bullish
auto_awesome

Analytical Summary

ORAMED PHARMACEUTICALS INC. shows strong fundamentals with top-quartile Return on Common Equity (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $159.6M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC None
FCF / Share $-0.00 ↗
Trailing P/E 2.1x
Price / Book —
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

80-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$78.16M
↑ +488.2% —
Operating Margin Operating profit as % of sales
-225.0%
↑ +49.2% —
FCF / Share Free cash flow per share
$-0.00
↑ +93.1% —
Long-Term Debt Long-term obligations
$74.55M
↑ +1324.3% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
0
Returns
93
Cash Quality
17

Dividend History

Dividend / share · sourced from SEC filings
$0.25 Latest / share

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 20 years · 80 quarters